William Blair：2026年第二季度美国生物制药市场回顾报告（英文版）（27页）.pdf

1、The Quarterly Rx:Q2 2026 U.S.Biopharma RecapJuly 2026Q2 2026 U.S.Market Summary Key TakeawaysThe biopharma market closed the first half of 2026 with momentum across the field,as IPOs found their footing,private capital kept pace,and active M&A gave the sector more ways to win despite a choppy macro

2、backdropStrong Kickoff:Carrying the Momentum Biopharmas rally accelerated into the final whistle of H1,with the XBI closing+23.9%in Q2 and reaching a 5-year high Broader markets reached record highs as resilient earnings,a small-cap-led advance,and renewed risk appetite outran geopolitical and macro

3、 noise despite expectations for an impending rate hike Healthcare kept decoupling as the XBI outran the XLV(1)as a reopened IPO window and robust M&A pulled capital toward higher-beta,catalyst-driven biopharma stocks Biopharma posted the largest weighting gain in the June 2026 Russell 2000 rebalance

4、,now the second-largest subsector at 9.5%,behind only banksStar Striker:AI Commands the Field SpaceXs record$86B IPO alongside confidential S-1s from Anthropic/OpenAI may keep markets watching the tech scoreboard,but we see minimal spillover to healthcare specialist flows;biopharma IPO read-through

5、hinges more on volatility and risk appetite AI drug discovery became the magnet for private biopharma capital,capturing 40%of Q2 proceeds,up from 22%for full-year 2025 AI platforms were the MVP(most valuable partnership)of H1,representing 23%of all licensing and collaboration dealsLifting the Cup:Pr

6、ivate Capital Advances Private financings stayed busy in Q2:68 deals raised$8.0B in total proceeds Bigger checks did the heavy lifting:fewer deals,as average round size swelled to$117M and 34%of rounds cleared$100M Crossover investors stayed active as the IPO window reopened,providing a vote of conf